ES2959443T3 - Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación - Google Patents

Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación Download PDF

Info

Publication number
ES2959443T3
ES2959443T3 ES13751899T ES13751899T ES2959443T3 ES 2959443 T3 ES2959443 T3 ES 2959443T3 ES 13751899 T ES13751899 T ES 13751899T ES 13751899 T ES13751899 T ES 13751899T ES 2959443 T3 ES2959443 T3 ES 2959443T3
Authority
ES
Spain
Prior art keywords
cell
domain
car
cells
signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13751899T
Other languages
English (en)
Spanish (es)
Inventor
Carl H June
John Scholler
Avery Posey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Application granted granted Critical
Publication of ES2959443T3 publication Critical patent/ES2959443T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13751899T 2012-02-22 2013-02-22 Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación Active ES2959443T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601907P 2012-02-22 2012-02-22
PCT/US2013/027361 WO2013126729A1 (en) 2012-02-22 2013-02-22 Use of the cd2 signaling domain in second-generation chimeric antigen receptors

Publications (1)

Publication Number Publication Date
ES2959443T3 true ES2959443T3 (es) 2024-02-26

Family

ID=49006248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13751899T Active ES2959443T3 (es) 2012-02-22 2013-02-22 Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación

Country Status (15)

Country Link
US (5) US9783591B2 (enExample)
EP (2) EP2817331B1 (enExample)
JP (1) JP2015509716A (enExample)
KR (1) KR20140127829A (enExample)
CN (1) CN104136458A (enExample)
AU (1) AU2013222284A1 (enExample)
BR (1) BR112014020502A2 (enExample)
CA (1) CA2864489C (enExample)
EA (1) EA201491573A1 (enExample)
ES (1) ES2959443T3 (enExample)
IL (1) IL233993A0 (enExample)
IN (1) IN2014DN06522A (enExample)
MX (1) MX2014010185A (enExample)
SG (1) SG11201404284SA (enExample)
WO (1) WO2013126729A1 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014020502A2 (pt) * 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US11041021B2 (en) 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
RS63601B1 (sr) * 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
RU2751362C2 (ru) 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
US11248058B2 (en) 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN105198790B (zh) * 2015-04-20 2018-02-16 范国煌 促进双阴性t细胞体外增殖的四环化合物
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11370845B2 (en) 2015-06-24 2022-06-28 Keio University Anti-glypican-1-immunizing antigen receptor
WO2017011316A1 (en) * 2015-07-10 2017-01-19 The Trustees Of The University Of Pennsylvania Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017040195A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
MX2018005618A (es) * 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CN110699371A (zh) * 2016-03-18 2020-01-17 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2017190096A1 (en) 2016-04-29 2017-11-02 University Of Florida Research Foundation Incorporated Chimeric antigen receptors and uses thereof
EP4122958A1 (en) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CN106754725A (zh) * 2016-12-26 2017-05-31 北京普瑞金科技有限公司 一种嵌合抗原受体t细胞及其制备方法与应用
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
KR20190130608A (ko) 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US20200283501A1 (en) 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
CN107880128B (zh) * 2017-12-21 2021-03-02 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN111867619A (zh) 2018-01-03 2020-10-30 曲生物制品公司 过继性细胞治疗的先天寻靶
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
CN110129369B (zh) * 2018-02-09 2023-10-13 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
EP3826625A4 (en) 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US12168781B2 (en) 2018-12-06 2024-12-17 Kirin Holdings Kabushiki Kaisha Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells
US20220062341A1 (en) 2018-12-26 2022-03-03 Kirin Holdings Kabushiki Kaisha Modified tcr and production method therefor
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
TW202042824A (zh) 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體（CAR）T細胞療法
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
CN115698285A (zh) * 2020-02-14 2023-02-03 小利兰·斯坦福大学董事会 具有cd2激活的嵌合抗原受体
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for generating engineered memory-like nk cells and compositions thereof
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
AU2021347359A1 (en) * 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
WO2022086620A1 (en) * 2020-10-20 2022-04-28 The Methodist Hospital System Psma-targeted immunotherapies for cancers
WO2022087453A1 (en) * 2020-10-22 2022-04-28 Lyell Immunopharma, Inc. Chimeric activation receptors
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US20240254441A1 (en) 2021-06-04 2024-08-01 Kirin Holdings Kabushiki Kaisha Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｌａｍｐ１抗体およびその使用
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
US20230407252A1 (en) * 2022-04-28 2023-12-21 Allogene Therapeutics, Inc. Methods for donor cell analysis
US20250295773A1 (en) * 2022-05-10 2025-09-25 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030171546A1 (en) * 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140060541A (ko) * 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
EP2817330B1 (en) * 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
BR112014020502A2 (pt) * 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
KR20210149195A (ko) * 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
RU2729401C2 (ru) * 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
EP3712171A1 (en) * 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10093746B2 (en) * 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201900885VA (en) * 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2019210207A2 (en) * 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2020069405A1 (en) * 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) * 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
AU2019404302A1 (en) * 2018-12-19 2021-08-05 The Trustees Of The University Of Pennsylvania Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
TW202042824A (zh) * 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體（CAR）T細胞療法
US20200370013A1 (en) * 2019-05-20 2020-11-26 The Trustees Of The University Of Pennsylvania Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors

Also Published As

Publication number Publication date
IL233993A0 (en) 2014-09-30
US20180037625A1 (en) 2018-02-08
US9783591B2 (en) 2017-10-10
IN2014DN06522A (enExample) 2015-06-12
EP4275699A2 (en) 2023-11-15
EP4275699A3 (en) 2024-01-03
JP2015509716A (ja) 2015-04-02
EA201491573A1 (ru) 2015-03-31
CN104136458A (zh) 2014-11-05
US20230242612A1 (en) 2023-08-03
MX2014010185A (es) 2014-11-14
EP2817331A1 (en) 2014-12-31
CA2864489C (en) 2023-08-08
SG11201404284SA (en) 2014-10-30
US11597754B2 (en) 2023-03-07
CA2864489A1 (en) 2013-08-29
BR112014020502A2 (pt) 2019-09-24
WO2013126729A1 (en) 2013-08-29
US10501519B2 (en) 2019-12-10
US20140370045A1 (en) 2014-12-18
US12234274B2 (en) 2025-02-25
EP2817331B1 (en) 2023-08-30
KR20140127829A (ko) 2014-11-04
AU2013222284A1 (en) 2014-08-07
EP2817331A4 (en) 2015-09-30
US20210371495A1 (en) 2021-12-02
US20190352369A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
US12234274B2 (en) Use of the CD2 signaling domain in second-generation chimeric antigen receptors
US20240018271A1 (en) Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody
US20230181643A1 (en) Use of trans-signaling approach in chimeric antigen receptors
ES2816450T3 (es) Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
ES2733525T3 (es) Métodos para evaluar la adecuación de los linfocitos T transducidos para su administración
US20210277114A1 (en) Car based immunotherapy
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
AU2013222267A1 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
HK40102427A (en) Use of the cd2 signaling domain in second-generation chimeric antigen receptors
HK40040144A (en) Enhancing activity of car t cells by co-introducing a bispecific antibody